Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Raptiva PML Case Brings Another REMS

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA wants black-box warning, new safety plan for psoriasis drug.

You may also be interested in...



Raptiva Withdrawal Shows Comparative Safety Focus From New, Decisive FDA

Market withdrawal of Genentech's psoriasis drug Raptiva (efalizumab) shows FDA under new leadership acting decisively on drug safety - especially in cases where comparable treatment alternatives exist

Raptiva Withdrawal Shows Comparative Safety Focus From New, Decisive FDA

Market withdrawal of Genentech's psoriasis drug Raptiva (efalizumab) shows FDA under new leadership acting decisively on drug safety - especially in cases where comparable treatment alternatives exist

Genentech Aborts Raptiva Amidst Reports Of Fatal Brain Infection

Risk management program couldn't save psoriasis drug. Decision is final, firm says.

Related Content

Topics

UsernamePublicRestriction

Register

PS066896

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel